A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles

Contraception

Volumn 69, Issue 4, 2004, Pages 271-278

  Gaspard, U ^a   Endrikat, J ^b   Desager, J P ^c   Buicu, C ^a   Gerlinger, C ^b   Heithecker, R ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b BAYER PHARMA AG   (Germany)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Desogestrel; Drospirenone; Ethinylestradiol; Lipids; Oral contraceptives

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN E; DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG TARGETING; FEMALE; HUMAN; HUMAN EXPERIMENT; LIPID ANALYSIS; LIPID METABOLISM; LIPOPROTEIN METABOLISM; LOW DRUG DOSE; MEASUREMENT; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; ANDROSTENES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CONTRACEPTIVES, ORAL, COMBINED; DESOGESTREL; ETHINYL ESTRADIOL; FEMALE; HUMANS; MENSTRUAL CYCLE; PROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 1642329996     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2003.11.003     Document Type: Article

References (31)

1. The European Agency for the Evaluation of Medicinal Products (EMEA). Committee for proprietary medicinal products (CPMP). Note for guidance on clinical investigation of steroid contraceptives in women. 17 February 2000 CPMP/EWP/519/98.
2. Crook D., Godsland I. Safety of modern oral contraceptives. Contraception. 57:1998;189-201.
3. Tikkanen M.J. The effect of progestins on plasma lipids. Sitruk-Ware R., Mishell D.R. Jr. Progestins and antiprogestins in clinical practice. 2000;355-368 Marcel Dekker Inc, New York.
4. Nofer J.R., Kehrel B., Folker M., Levkau B., Assmann G., von Ekardstein A. HDL and arteriosclerosis beyond reverse cholesterol transport. Atherosclerosis. 161:2002;1-16.
5. Skouby S.O. The rationale for a wider range of progestogens. Climacteric. 3:2000;14-20.
6. Muhn P., Krattenmacher R., Beier S., Elger W., Schillinger E. Drospirenone a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception. 51:1995;99-110.
7. Foidart J.M., Oelkers W., Heithecker R. Drospirenone a novel progestogen with antimineralocorticoid and antiandrogenic activity: major breakthrough in tomorrow's oral contraception. Gynecol Snapshot. 3:1995;13-17.
8. Fuhrmann U., Krattenmacher R., Slater E.P., Fritzemeier K.H. The novel progestin drospirenone and its natural counterpart progesterone biochemical profile and antiandrogenic potential. Contraception. 54:1996;243-251.
9. Huber J., Foidart J.M., Wuttke W., Bouw G.M., Gerlinger C., Heithecker R. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care. 5:2000;25-34.
10. Parsey K.S., Pong A. An open-label, multi-centered study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception. 61:2000;105-111.
11. Oelkers W.E., Foidart J.M., Dombrovich N., Welter A., Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance and lipid metabolism. J Clin Endocrinol Metab. 80:1995;1816-1821.
12. Gaspard U., Scheen A., Endrikat J., et al. A randomized 13 cycles study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. Contraception. 67:2003;423-429.
13. Lopes-Virella M.F., Stone M., Ellis S., Colwell J.A. Cholesterol determination in high density lipoproteins separated by three different methods. Clin Chem. 23:1977;882-884.
14. Chapman M.J., Goldstein S., Lagrange D., Laplaud P.M. A density gradient ultracentrifugation procedure for the isolation of the major lipoprotein classes from human serum. J Lipid Res. 22:1981;339-357.
15. Endrikat J., Klipping C., Cronin M., et al. An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20μg ethinylestradiol and 100μg levonorgestrel on hemostatic, lipids and carbohydrate metabolism variables. Contraception. 65:2002;215-221.
16. Gaspard U.J., Demeyer F., Jaminet C.B., Scheen A.J., Lefebvre P.J. Influence of two low-dose oral contraceptives containing ethinylestradiol (20μg) and desogestrel or gestodene on carbohydrate metabolism during 1 year of use. Gynecol Endocrinol. 10:(Suppl 2):1996;179-181.
17. Robinson G.E., Registrar S. Low-dose combined oral contraceptives. Br J Obstet Gynaecol. 101:1994;1036-1041.
18. Lobo R.A., Skinner J.B., Lippman J.S., Cirillo S.J. Plasma lipids and desogestrel and ethinylestradiol a meta-analysis. Fertil Steril. 65:1996;1100-1109.
19. Crook D. Multicenter study of endocrine function and plasma lipids and lipoproteins in women using oral contraceptives containing desogestrel progestin. Contraception. 55:1997;219-224.
20. Jacobs D.R., Mebane I.L., Bangdiwala S.I., Criqui M.H., Tyroler H.A. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol. 131:1990;32-47.
21. Teichmann A. Metabolic profile of six oral contraceptives containing norgestimate, gestodene and desogestrel. Int J Fertil. 40:1995;98-104.
22. Foulon T., Payen N., Laporte F., et al. Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size. Contraception. 64:2001;11-16.
23. Knopp R.H., Broyles F.E., Cheung M., Moore K., Marcovina S., Chander W.L. Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel. Contraception. 63:2001;1-11.
24. Sacks F.M., Walsh B.W. Effects of low dose oral contraceptives on very low density and low density lipoprotein metabolism. J Clin Invest. 91:1993;2126-2132.
25. Castelli W.P. The triglyceride issue a view from Framingham. Am Heart J. 112:1986;432-437.
26. Stensvold I., Tverdal A., Urdal P., Graff-Iversen S. Non-fasting serum triglyceride concentrations and mortality from coronary heart disease and any cause in middle aged Norwegian women. Br Med J. 307:1993;1318-1322.
27. Godsland I.F., Crook D. Update on the metabolic effects of steroidal contraceptives and their relationship to cardiovascular disease risk. Am J Obstet Gynecol. 170:1994;1528-1536.
28. De Graaf J., Swinkels D.W., Demacker P.N., de Haan A.F., Stalenhoef A.F. Differences in the low density lipoprotein subfraction profile between oral contraceptive users and controls. J Clin Endocrinol Metab. 76:1993;197-202.
29. NIH Consensus Development Panel on Triglyceride, High Density Lipoprotein and Coronary Heart Disease. JAMA 1993;269:505-10.
30. Hulley S.B., Rosenman R.H., Bawol R.D., Brand R.J. Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. N Engl J Med. 302:1982;1383-1389.
31. Fotherby K. Oral contraceptives and lipids. BMJ. 298:1989;1049-1050.